Coeptis Therapeutics Stock (NASDAQ:COEP), Analyst Ratings, Price Targets, Predictions

The latest price target for Coeptis Therapeutics (NASDAQ: COEP) was reported by Ladenburg Thalmann on September 22, 2023. The analyst firm set a price target for $3.00 expecting COEP to rise to within 12 months (a possible 834.58% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Coeptis Therapeutics (NASDAQ: COEP) was provided by Ladenburg Thalmann, and Coeptis Therapeutics initiated their buy rating.

There is no last upgrade for Coeptis Therapeutics.

There is no last downgrade for Coeptis Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coeptis Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coeptis Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.

While ratings are subjective and will change, the latest Coeptis Therapeutics (COEP) rating was a initiated with a price target of $0.00 to $3.00. The current price Coeptis Therapeutics (COEP) is trading at is $0.32, which is within the analyst’s predicted range.